Clinical Trials Directory

Trials / Completed

CompletedNCT04070742

Dermal Phototoxicity Study

A 4-Day, Randomized, Controlled Study to Evaluate the Phototoxicity Potential of FMX-101, 4% in Healthy Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
32 (actual)
Sponsor
Vyne Therapeutics Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Dermal Safety study to determine the Phototoxicity Potential of FMX-101 4% in Healthy Volunteers

Conditions

Interventions

TypeNameDescription
DRUGFMX101

Timeline

Start date
2016-08-17
Primary completion
2016-09-07
Completion
2016-10-01
First posted
2019-08-28
Last updated
2019-09-11

Regulatory

Source: ClinicalTrials.gov record NCT04070742. Inclusion in this directory is not an endorsement.